A randomized Phase 2 study of pemetrexed in combination with cisplatin or carboplatin as adjuvant chemotherapy in patients with completely resected stage IB or II Non-Small-Cell Lung Cancer. Issue 3 (December 2015)

• Record Type: Journal Article
• Authors: Schmid-Bindert, Gerald; Engel-Riedel, Walburga; Reck, Martin; Schuette, Wolfgang; Stöhlmacher, Jan; Fischer, Jürgen R.; Mazières, Julien; Chouaid, Christos; Wolf, Martin; Vinolas, Nuria; Soldatenkova, Victoria; Ripoche, Veronique; Nguyen, Tuan; Visseren-Grul, Carla
• Is Part Of: Lung cancer. Volume 90:Issue 3(2015:Dec.)
• Page Start: 397
• Page End: 404
• Publication Date: 2015-12
• Subjects: AE adverse event -- CTCAE common terminology criteria for adverse events -- CI confidence interval -- DFS disease-free survival -- IHC immunohistochemistry -- i.v. intravenous -- MedDRA medical dictionary for regulatory activities -- NSCLC Non-Small-Cell Lung Cancer -- OS overall survival -- SAE serious adverse event -- SNP single nucleotide polymorphism -- TEAE treatment emergent adverse event -- TREAT Trial on Refinement of Early stage lung cancer Adjuvant Therapy; Pemetrexed -- NSCLC -- Feasibility -- Adjuvant treatment; Lungs -- Cancer -- Periodicals; Lung Neoplasms -- Abstracts; Lung Neoplasms -- Periodicals; Poumons -- Cancer -- Périodiques; Lungs -- Cancer; Periodicals; Electronic journals; Electronic journals; 616.99424
• DOI: 10.1016/j.lungcan.2015.11.007
• Languages: English
• ISSNs: 0169-5002

Abstract

Highlights: Feasibility of adjuvant cisplatin or carboplatin + pemetrexed in Stage IB/II NSCLC. Feasibility definition based on safety, tolerability, and dose-intensity parameters. Neither treatment met the pre-defined feasibility level >60% of patients. Feasibility >81% (both treatments) in a post-hoc analysis considering only safety. Both treatments showed good safety-related feasibility and tolerability. Abstract: Objectives: We investigated the feasibility of cisplatin or carboplatin combined with pemetrexed as adjuvant treatment in patients with completely resected Stage IB/II Non-Small-Cell Lung Cancer (NSCLC). Materials and methods: Patients in this multicenter, open-label, parallel-group, non-comparative Phase 2 study were randomized (1:1) to pemetrexed (500 mg/m 2 ) with either cisplatin (75 mg/m 2 ) or carboplatin (AUC5) for 4 cycles of 21 days. The primary endpoint was treatment feasibility (defined as 4 cycles completed with no cycle delay >42 days and ≤2 dose reductions, with a median relative dose intensity (RDI) ≥95% [overall]; and no Grade ≥3 toxicities at the follow-up visit 30 days after last drug administration). Secondary objectives included overall survival (OS) and safety. Results: We randomized 122 patients and treated 118. 71.9% (46/64) of patients in pemetrexed + cisplatin and 88.9% (48/54) in pemetrexed + carboplatin completed 4 cycles (median RDI >97% for all compounds). Neither treatment met the pre-defined feasibility level >60% of patients: 59.4% (95% confidence interval [CI]: 46.4;71.5) pemetrexed + cisplatin; 50.0% (95%CI: 36.1;63.9) in pemetrexed + carboplatin. In a post-hoc analysis considering only safety, both regimens were feasible with 81.3% (95%CI: 69.5;89.9) in pemetrexed + cisplatin and 90.7% (95%CI: 79.7;96.9) in pemetrexed + carboplatin. OS rates for both groups were 82–83% after 3 years and 80–83% after 5 years. Treatment-related Grade ≥3 adverse events (mostly hematological) were experienced by approximately 30% of patients in each group. Conclusion: Although the study did not meet the primary objective, both treatment groups demonstrated good safety-related feasibility and tolerability as adjuvant treatment in patients with completely resected Stage IB/II NSCLC.